0001628280-22-019311 | 40-F/A | XBRL Viewer

COVER	12 Months Ended
Mar. 31, 2022 shares
Entity Addresses [Line Items]
Document Type	40-F/A
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Mar. 31, 2022
Current Fiscal Year End Date	--03-31
Entity File Number	001-40673
Entity Registrant Name	Cybin Inc.
Entity Incorporation, State or Country Code	A6
Entity Primary SIC Number	2834
Entity Address, Address Line One	100 King Street West, Suite 5600
Entity Address, City or Town	Toronto
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	M5X 1C9
City Area Code	908
Local Phone Number	764-8385
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	CYBN
Security Exchange Name	NYSEAMER
Amendment Flag	true
Amendment Description	To furnish Exhibit 101 to the Form-F, which provides certain items from our Form 40-F formatted in XBRL
Entity Central Index Key	0001833141
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding	164,640,303
Annual Information Form	true
Audited Annual Financial Statements	true
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Business Contact
Entity Addresses [Line Items]
Contact Personnel Name	CT Corporation System
Entity Address, Address Line One	1015 15th Street N.W., Suite 1000
Entity Address, City or Town	Washington
Entity Address, State or Province	DC
Entity Address, Postal Zip Code	20005
City Area Code	202
Local Phone Number	572-3133

Label	Element	Value
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	$ 0.25
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.25
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.64
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.25
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.64
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.64
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.75
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	0.75
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	3.25
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	2.25
Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted	cybn_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted	$ 3.40
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	8500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	8500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	8500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	9500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	9500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	9500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	8500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	9500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	8500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	8500.00%
Expected Volatility, Other Equity Instruments Granted	cybn_ExpectedVolatilityOtherEquityInstrumentsGranted	85.00%
Expense Arising From Passage of Time, Contingent Liabilities Recognised In Business Combination	cybn_ExpenseArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination	$ 316,000
Expense Arising From Passage of Time, Contingent Liabilities Recognised In Business Combination	cybn_ExpenseArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination	$ 482,000
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	934,103
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	2,690,078
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	362,418.1
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	93,410.3
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	269,007.8
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	51,163
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	42,247.3
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	15,777.1
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	18,788.5
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	9,392.6
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	28,903
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	31,721.5
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	15,611.4
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	41,028.2
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	17,239.5
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	90,546
Number Of Shares Issued Through Contingent Consideration, Equity	cybn_NumberOfSharesIssuedThroughContingentConsiderationEquity	22,428.3
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	2 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	2 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	2 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	5 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	5 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	5 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	2 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	5 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	3 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	3 years
Other Equity Instruments Life, Other Equity Instruments Granted	cybn_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted	2 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	5 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Share Price	cybn_SharePrice	$ 0.25
Share Price	cybn_SharePrice	0.25
Share Price	cybn_SharePrice	0.25
Share Price	cybn_SharePrice	0.64
Share Price	cybn_SharePrice	2.25
Share Price	cybn_SharePrice	3.40
Share Price	cybn_SharePrice	13.43
Share Price	cybn_SharePrice	13.54
Share Price	cybn_SharePrice	9.99
Share Price	cybn_SharePrice	0.25
Share Price	cybn_SharePrice	0.64
Share Price	cybn_SharePrice	0.64
Share Price	cybn_SharePrice	0.75
Share Price	cybn_SharePrice	0.75
Share Price	cybn_SharePrice	2.12
Share Price	cybn_SharePrice	2.12
Share Price	cybn_SharePrice	3.83
Share Price	cybn_SharePrice	$ 10.20
Number Of Shares Issued Through Acquisition Of Subsidiary, Equity	cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity	8,688,330
Number Of Shares Issued Through Acquisition Of Subsidiary, Equity	cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity	868,833
Number Of Shares Issued Through Acquisition Of Subsidiary, Equity	cybn_NumberOfSharesIssuedThroughAcquisitionOfSubsidiaryEquity	868,833
Number Of Shares Issued Through Share Offering, Equity	cybn_NumberOfSharesIssuedThroughShareOfferingEquity	15,246,000
Number Of Shares Issued Through Share Offering, Equity	cybn_NumberOfSharesIssuedThroughShareOfferingEquity	10,147,600
Number Of Shares Issued Through Share Offering, Equity	cybn_NumberOfSharesIssuedThroughShareOfferingEquity	15,246,000
Number Of Shares Issued Through Share Offering, Equity	cybn_NumberOfSharesIssuedThroughShareOfferingEquity	10,147,600
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Expected Dividend As Percentage, Other Equity Instruments Granted	cybn_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted	0.00%
Increase (Decrease) Through Share Subscriptions Reversed, Equity	cybn_IncreaseDecreaseThroughShareSubscriptionsReversedEquity	$ 700,000
Increase (Decrease) Through Share Subscriptions Reversed, Equity	cybn_IncreaseDecreaseThroughShareSubscriptionsReversedEquity	700,000
Increase (Decrease) Through Share Subscriptions Reversed, Equity	cybn_IncreaseDecreaseThroughShareSubscriptionsReversedEquity	164,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	2,668,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	948,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	49,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	1,388,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	5,899,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	970,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	1,299,000
Warrants and Rights Outstanding	cybn_WarrantsAndRightsOutstanding	$ 12,000
Number Of Shares Reversed Through Share Subscriptions, Equity	cybn_NumberOfSharesReversedThroughShareSubscriptionsEquity	2,799,982
Number Of Shares Reversed Through Share Subscriptions, Equity	cybn_NumberOfSharesReversedThroughShareSubscriptionsEquity	6,569,772
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	38.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	38.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	38.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	182.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	121.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	121.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	36.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	38.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	32.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	32.00%
Risk Free Interest Rate, Other Equity Instruments Granted	cybn_RiskFreeInterestRateOtherEquityInstrumentsGranted	0.42%
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	$ 1,539,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	1,539,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	4,251,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	4,251,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	1,018,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	686,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	458,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	633,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	317,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	706,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	629,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	236,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	551,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	233,000
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	905,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	16,307,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	5,660,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	1,526,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	1,126,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	227,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	12,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	43,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	23,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	18,103,000
Deferred Tax Assets, Gross	cybn_DeferredTaxAssetsGross	6,821,000
Interest Income, Fair Value Measurement, Assets	cybn_InterestIncomeFairValueMeasurementAssets	$ 21,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	18,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	2,000,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	295,309
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	96,034
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	199,275
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	16,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	2,590,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	868,740
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	658,860
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	29,451,284
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	658,860
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	868,740
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	0
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	14,725,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	2,000,125
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	56,250
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	127,600
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	16,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	2,590,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	7,623,000
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	2 years 7 months 2 days
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	1 year 10 months 6 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	29,957,860
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	868,740
Number Of Share Options Assumed In Share Consolidation In Share-Based Payment Arrangement	cybn_NumberOfShareOptionsAssumedInShareConsolidationInShareBasedPaymentArrangement	202,338
Weighted Average Exercise Price Of Share Options Assumed In Share Consolidation In Share-Based Payment Arrangement	cybn_WeightedAverageExercisePriceOfShareOptionsAssumedInShareConsolidationInShareBasedPaymentArrangement	$ 0.6672
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.25
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.25
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.64
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.75
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	3.25
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	3.40
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	3.25
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.25
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.64
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.64
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	0.75
Exercise Price of Other Equity Instruments in Share-based Payment Arrangement	cybn_ExercisePriceOfOtherEquityInstrumentsInShareBasedPaymentArrangement	$ 0.25
Class of Warrant or Right, Outstanding	cybn_ClassOfWarrantOrRightOutstanding	2,000,000
Class of Warrant or Right, Outstanding	cybn_ClassOfWarrantOrRightOutstanding	1,150,000
Other Equity Instruments, Stock Price Trigger	cybn_OtherEquityInstrumentsStockPriceTrigger	5.00
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	24 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	24 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	24 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	24 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	60 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	60 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	60 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	24 months
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	24 months
Other Equity Instruments, Threshold Consecutive Trading Days	cybn_OtherEquityInstrumentsThresholdConsecutiveTradingDays	10
Number Of Shares Issued Through Conversion Of Convertible Debt, Equity	cybn_NumberOfSharesIssuedThroughConversionOfConvertibleDebtEquity	1,200,000
Number Of Shares Issued Through Conversion Of Convertible Debt, Equity	cybn_NumberOfSharesIssuedThroughConversionOfConvertibleDebtEquity	1,200,000
Other Equity Instruments, Threshold Trading Days	cybn_OtherEquityInstrumentsThresholdTradingDays	30
Increase (Decrease) Through Contributed Capital, Equity	cybn_IncreaseDecreaseThroughContributedCapitalEquity	$ 164,000
Increase (Decrease) Through Contributed Capital, Equity	cybn_IncreaseDecreaseThroughContributedCapitalEquity	164,000
Increase (Decrease) Through Issuance of Warrants, Equity	cybn_IncreaseDecreaseThroughIssuanceOfWarrantsEquity	(1,225,000)
Increase (Decrease) Through Issuance of Warrants, Equity	cybn_IncreaseDecreaseThroughIssuanceOfWarrantsEquity	1,225,000
Increase (Decrease) Through Issuance of Warrants, Equity	cybn_IncreaseDecreaseThroughIssuanceOfWarrantsEquity	0
Increase (Decrease) Through Issuance of Warrants, Equity	cybn_IncreaseDecreaseThroughIssuanceOfWarrantsEquity	(1,332,000)
Increase (Decrease) Through Issuance of Warrants, Equity	cybn_IncreaseDecreaseThroughIssuanceOfWarrantsEquity	1,332,000
Increase (Decrease) Through Issuance of Warrants, Equity	cybn_IncreaseDecreaseThroughIssuanceOfWarrantsEquity	0
Adjustments For Gains (Losses) On Fair Value Adjustment, Investments	cybn_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestments	(29,000)
Adjustments For Gains (Losses) On Fair Value Adjustment, Investments	cybn_AdjustmentsForGainsLossesOnFairValueAdjustmentInvestments	$ 0
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	10,471,351
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	9,622,433
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	8,688,330
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	511,630
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	422,473
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	157,771
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	187,886
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	93,926
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	289,030
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	317,215
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	156,114
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	410,282
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	172,395
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	905,460
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	224,283
Number of Shares Issued Upon Conversion of Convertible Instruments	cybn_NumberOfSharesIssuedUponConversionOfConvertibleInstruments	380,230
Convertible Stock, Shares Issued upon Conversion, Percentage	cybn_ConvertibleStockSharesIssuedUponConversionPercentage	100.00%
Adjustments For Expense Arising From Passage of Time, Contingent Liabilities Recognised In Business Combination	cybn_AdjustmentsForExpenseArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination	$ 316,000
Adjustments For Expense Arising From Passage of Time, Contingent Liabilities Recognised In Business Combination	cybn_AdjustmentsForExpenseArisingFromPassageOfTimeContingentLiabilitiesRecognisedInBusinessCombination	$ 482,000
Conversion Of Stock, Exchange Rate	cybn_ConversionOfStockExchangeRate	10
Increase (Decrease) Through Share Offering, Equity	cybn_IncreaseDecreaseThroughShareOfferingEquity	$ 26,293,000
Increase (Decrease) Through Share Offering, Equity	cybn_IncreaseDecreaseThroughShareOfferingEquity	5,900,000
Increase (Decrease) Through Share Offering, Equity	cybn_IncreaseDecreaseThroughShareOfferingEquity	32,193,000
Increase (Decrease) Through Share Offering, Equity	cybn_IncreaseDecreaseThroughShareOfferingEquity	31,507,000
Increase (Decrease) Through Share Offering, Equity	cybn_IncreaseDecreaseThroughShareOfferingEquity	0
Increase (Decrease) Through Share Offering, Equity	cybn_IncreaseDecreaseThroughShareOfferingEquity	31,507,000
Adjustments For Gains (Losses) On Change In Fair Value For Contingent Liabilities Recognised In Business Combination	cybn_AdjustmentsForGainsLossesOnChangeInFairValueForContingentLiabilitiesRecognisedInBusinessCombination	(3,380,000)
Adjustments For Gains (Losses) On Change In Fair Value For Contingent Liabilities Recognised In Business Combination	cybn_AdjustmentsForGainsLossesOnChangeInFairValueForContingentLiabilitiesRecognisedInBusinessCombination	$ 0
Number Of Shares Issued Through Exercise Of Warrants, Equity	cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity	815,047
Number Of Shares Issued Through Exercise Of Warrants, Equity	cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity	3,231,261
Number Of Shares Issued Through Exercise Of Warrants, Equity	cybn_NumberOfSharesIssuedThroughExerciseOfWarrantsEquity	1,000,000
Shares Issued, Price Per Share	cybn_SharesIssuedPricePerShare	$ 12.40
Adjustments For Listing Fees	cybn_AdjustmentsForListingFees	$ 0
Adjustments For Listing Fees	cybn_AdjustmentsForListingFees	1,467,000
Adjustments For Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Investments	cybn_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossInvestments	0
Adjustments For Impairment Loss (Reversal Of Impairment Loss) Recognized In Profit Or Loss, Investments	cybn_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognizedInProfitOrLossInvestments	63,000
Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation	cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation	(309,000)
Adjustments For Unrealized Gain (Loss) On Foreign Currency Translation	cybn_AdjustmentsForUnrealizedGainLossOnForeignCurrencyTranslation	(71,000)
Cash Paid Upon Close of Acquisition	cybn_CashPaidUponCloseOfAcquisition	$ 65,000
Warrant Reserve, Exercise Price, Percentage Of Conversion Price	cybn_WarrantReserveExercisePricePercentageOfConversionPrice	125.00%
Cash Transferred, Annual Interest Rate	cybn_CashTransferredAnnualInterestRate	10.00%
Borrowings, Conversion Price, Percentage Of Equity Financing Offering Price	cybn_BorrowingsConversionPricePercentageOfEquityFinancingOfferingPrice	80.00%
(Increase (Decrease) Through Share Options Forfeited In Share Based Payment Award, Equity	cybn_IncreaseDecreaseThroughShareOptionsForfeitedInShareBasedPaymentAwardEquity	$ 124,000
(Increase (Decrease) Through Share Options Forfeited In Share Based Payment Award, Equity	cybn_IncreaseDecreaseThroughShareOptionsForfeitedInShareBasedPaymentAwardEquity	(124,000)
(Increase (Decrease) Through Share Options Forfeited In Share Based Payment Award, Equity	cybn_IncreaseDecreaseThroughShareOptionsForfeitedInShareBasedPaymentAwardEquity	0
(Increase (Decrease) Through Share Options Forfeited In Share Based Payment Award, Equity	cybn_IncreaseDecreaseThroughShareOptionsForfeitedInShareBasedPaymentAwardEquity	401,000
(Increase (Decrease) Through Share Options Forfeited In Share Based Payment Award, Equity	cybn_IncreaseDecreaseThroughShareOptionsForfeitedInShareBasedPaymentAwardEquity	(401,000)
(Increase (Decrease) Through Share Options Forfeited In Share Based Payment Award, Equity	cybn_IncreaseDecreaseThroughShareOptionsForfeitedInShareBasedPaymentAwardEquity	0
Increase (Decrease) Through Amalgamation, Equity	cybn_IncreaseDecreaseThroughAmalgamationEquity	1,596,000
Increase (Decrease) Through Amalgamation, Equity	cybn_IncreaseDecreaseThroughAmalgamationEquity	23,000
Increase (Decrease) Through Amalgamation, Equity	cybn_IncreaseDecreaseThroughAmalgamationEquity	1,619,000
Adjustments For Option Issuance	cybn_AdjustmentsForOptionIssuance	0
Adjustments For Option Issuance	cybn_AdjustmentsForOptionIssuance	$ 23,000
Number Of Shares Issued Through Amalgamation, Equity	cybn_NumberOfSharesIssuedThroughAmalgamationEquity	2,128,295
Number Of Shares Issued Through Amalgamation, Equity	cybn_NumberOfSharesIssuedThroughAmalgamationEquity	2,128,295
Number of Shares Issued as Convertible Instruments	cybn_NumberOfSharesIssuedAsConvertibleInstruments	868,833
Increase (Decrease) Through Conversion of Convertible Instruments, Equity, Shares	cybn_IncreaseDecreaseThroughConversionOfConvertibleInstrumentsEquityShares	(184,116)
Capital Market Expense	cybn_CapitalMarketExpense	$ 7,277,000
Capital Market Expense	cybn_CapitalMarketExpense	$ 2,118,000
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	$ 1.99
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	1.62
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	2.90
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	3.37
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	3.38
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	2.44
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	1.98
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	1.51
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	1.34
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	1.35
Convertible Stock, Conversion Price	cybn_ConvertibleStockConversionPrice	1.00
Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Share-based Payment Arrangement	cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement	1.13
Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Share-based Payment Arrangement	cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement	3.40
Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Share-based Payment Arrangement	cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement	2.25
Weighted Average Exercise Price Of Other Equity Instruments Exercised Or Vested In Share-based Payment Arrangement	cybn_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInShareBasedPaymentArrangement	$ 0
Adjustments For Increase (Decrease) In Accrued And Other Liabilities	cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities	$ 2,469,000
Adjustments For Increase (Decrease) In Accrued And Other Liabilities	cybn_AdjustmentsForIncreaseDecreaseInAccruedAndOtherLiabilities	$ 1,795,000
Number of Share Options on Accelerated Vesting Schedule	cybn_NumberOfShareOptionsOnAcceleratedVestingSchedule	1,031,250
Expense From Share-based Payment Transaction, Accelerated Cost	cybn_ExpenseFromShareBasedPaymentTransactionAcceleratedCost	$ 168,000
Deferred Tax Assets, Valuation Allowance	cybn_DeferredTaxAssetsValuationAllowance	18,103,000
Deferred Tax Assets, Valuation Allowance	cybn_DeferredTaxAssetsValuationAllowance	6,821,000
Impairment Loss Recognized In Profit Or Loss, Investments	cybn_ImpairmentLossRecognizedInProfitOrLossInvestments	0
Impairment Loss Recognized In Profit Or Loss, Investments	cybn_ImpairmentLossRecognizedInProfitOrLossInvestments	$ 63,000
Number of Share Options Held In Escrow	cybn_NumberOfShareOptionsHeldInEscrow	2,981,250
Number of Share Options Held In Escrow	cybn_NumberOfShareOptionsHeldInEscrow	8,475,000
Increase (Decrease) Through Private Placement, Equity	cybn_IncreaseDecreaseThroughPrivatePlacementEquity	$ 50,049,000
Increase (Decrease) Through Private Placement, Equity	cybn_IncreaseDecreaseThroughPrivatePlacementEquity	50,049,000
Business Development Expense	cybn_BusinessDevelopmentExpense	2,223,000
Business Development Expense	cybn_BusinessDevelopmentExpense	$ 907,000
Expected Forfeiture As Percentage, Other Equity Instruments Exercised Or Vested	cybn_ExpectedForfeitureAsPercentageOtherEquityInstrumentsExercisedOrVested	100.00%
Investor Relations Expense	cybn_InvestorRelationsExpense	$ 1,981,000
Investor Relations Expense	cybn_InvestorRelationsExpense	1,271,000
Equity Interest Of Acquirer, Contingent Consideration	cybn_EquityInterestOfAcquirerContingentConsideration	9,388,000
Aggregate Fair Value, Other Equity Instruments Exercised Or Vested	cybn_AggregateFairValueOtherEquityInstrumentsExercisedOrVested	3,000
Aggregate Fair Value, Other Equity Instruments Exercised Or Vested	cybn_AggregateFairValueOtherEquityInstrumentsExercisedOrVested	0
Aggregate Fair Value, Other Equity Instruments Exercised Or Vested	cybn_AggregateFairValueOtherEquityInstrumentsExercisedOrVested	$ 87,000
Number of Warrants Held In Escrow	cybn_NumberOfWarrantsHeldInEscrow	3,125,032
Number of Warrants Held In Escrow	cybn_NumberOfWarrantsHeldInEscrow	9,375,094
Non-Current Contingent Liabilities Recognised In Business Combination	cybn_NonCurrentContingentLiabilitiesRecognisedInBusinessCombination	$ 0
Non-Current Contingent Liabilities Recognised In Business Combination	cybn_NonCurrentContingentLiabilitiesRecognisedInBusinessCombination	$ 1,094,000
Equity Interest Of Acquirer, Contingent Consideration, Minimum Price Per Share	cybn_EquityInterestOfAcquirerContingentConsiderationMinimumPricePerShare	$ 7.50
Number Of Shares Issued Through Private Placement, Equity	cybn_NumberOfSharesIssuedThroughPrivatePlacementEquity	74,246,666
Number Of Shares Issued Through Private Placement, Equity	cybn_NumberOfSharesIssuedThroughPrivatePlacementEquity	3,706,600
Number Of Shares Issued Through Private Placement, Equity	cybn_NumberOfSharesIssuedThroughPrivatePlacementEquity	10,540,066
Share Subscriptions, Price Per Share	cybn_ShareSubscriptionsPricePerShare	$ 0.0001
Share Subscriptions, Price Per Share	cybn_ShareSubscriptionsPricePerShare	0.025
Share Subscriptions, Price Per Share	cybn_ShareSubscriptionsPricePerShare	$ 0.75
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant, Percent Of Total Shares Outstanding	cybn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfTotalSharesOutstanding	20.00%
Proceeds From Issuance Of Warrants	cybn_ProceedsFromIssuanceOfWarrants	$ 0
Proceeds From Issuance Of Warrants	cybn_ProceedsFromIssuanceOfWarrants	$ 5,900,000
Conversion Of Stock, Shares Issued Upon Conversion	cybn_ConversionOfStockSharesIssuedUponConversion	8,688,330
Current Contingent Liabilities Recognised In Business Combination	cybn_CurrentContingentLiabilitiesRecognisedInBusinessCombination	$ 2,646,000
Current Contingent Liabilities Recognised In Business Combination	cybn_CurrentContingentLiabilitiesRecognisedInBusinessCombination	$ 2,107,000
Convertible Stock, Shares Issued, Effective Price Per Share	cybn_ConvertibleStockSharesIssuedEffectivePricePerShare	$ 1.24
Convertible Stock, Shares Issued, Effective Price Per Share	cybn_ConvertibleStockSharesIssuedEffectivePricePerShare	$ 1.02
Accretion Of Convertible Debt	cybn_AccretionOfConvertibleDebt	$ 0
Accretion Of Convertible Debt	cybn_AccretionOfConvertibleDebt	10,000
Listing Fees Expense	cybn_ListingFeesExpense	533,000
Listing Fees Expense	cybn_ListingFeesExpense	$ 2,052,000
Share Subscriptions, Securities Called by Warrants, Percentage of Subscriptions	cybn_ShareSubscriptionsSecuritiesCalledByWarrantsPercentageOfSubscriptions	6.00%
Share Subscription, Fee Percentage	cybn_ShareSubscriptionFeePercentage	6.00%
Convertible Stock, Additional Amount Issuable	cybn_ConvertibleStockAdditionalAmountIssuable	$ 5,000
Share Subscription, Fee Percentage, Presidents List Orders	cybn_ShareSubscriptionFeePercentagePresidentsListOrders	1.50%
Proceeds From Issuance Of Subscriptions	cybn_ProceedsFromIssuanceOfSubscriptions	$ 45,000,000
Number of Shares Issued Through Subscription Receipts, Equity	cybn_NumberOfSharesIssuedThroughSubscriptionReceiptsEquity	60,000,000
Borrowings, Convertible, Conversion Price	cybn_BorrowingsConvertibleConversionPrice	$ 0.25
Conversion Of Stock, Shares Converted	cybn_ConversionOfStockSharesConverted	38,023
Other Equity Instruments, Trading Days, Minimum Notice	cybn_OtherEquityInstrumentsTradingDaysMinimumNotice	30 days
Class of Warrant or Right, Convertible, Conversion Ratio	cybn_ClassOfWarrantOrRightConvertibleConversionRatio	0.5
Class of Warrant or Right, Convertible, Conversion Ratio	cybn_ClassOfWarrantOrRightConvertibleConversionRatio	0.5
Proceeds From Issue of Ordinary Shares in Private Placement	cybn_ProceedsFromIssueOfOrdinarySharesInPrivatePlacement	$ 927,000
Contingent Liabilities Recognised in Business Combination, Remaining Payments	cybn_ContingentLiabilitiesRecognisedInBusinessCombinationRemainingPayments	$ 3,014,000
Business Combination, Contingent Liabilities, Share Price, Trading Price Multiplier	cybn_BusinessCombinationContingentLiabilitiesSharePriceTradingPriceMultiplier	10
Warrant Expiration Period Three [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	6 months 18 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	143,600
Warrant Expiration Period Nine [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	3 years 7 months 17 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	1,150,000
Warrant Expiration Period Six [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	1 year 10 months 2 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	7,623,000
Warrant Expiration Period Seven [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	3 years 2 months 15 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	13,575,000
Warrant Expiration Period Eight [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	3 years 4 months 20 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	2,000,125
Warrant Expiration Period Five [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	1 year 4 months 2 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	658,860
Warrant Expiration Period Four [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	7 months 2 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	2,590,000
Warrant Expiration Period One [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	2 months 15 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	2,018,000
Warrant Expiration Period Ten [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	1 year 10 months 6 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	868,740
Warrant Expiration Period Two [Member]
Weighted Average Remaining Contractual Life of Other Equity Instruments	cybn_WeightedAverageRemainingContractualLifeOfOtherEquityInstruments	2 months 26 days
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement, Accumulated	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangementAccumulated	199,275
Consultants [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	1 year
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Employee [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Director [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Consultants, Two [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	1 year
Certain Employees, Two [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Executive Officer [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Consultant [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	1 year
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 months
Executive Officers And Consultants [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Certain Employees, One [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	2 years
Directors And Executive Officers [Member]
Vesting Requirements For Share-Based Payment Arrangement, Vesting Period	cybn_VestingRequirementsForShareBasedPaymentArrangementVestingPeriod	24 months
Vesting, Six [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	83,330
Class of Warrant or Right, Number Of Warrants Vesting Monthly	cybn_ClassOfWarrantOrRightNumberOfWarrantsVestingMonthly	16,666
Share-based Payment, Vesting, Period Two [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	700,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	1,400,000
Share-based Payment, Vesting, Period Five [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	700,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	400,000
Share-based Payment, Vesting, Period Four [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	150,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	150,000
Vesting, Seven [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	766,670
Share-based Payment, Vesting, Period Three [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	300,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	300,000
Other Equity Instruments in Share-based Payment Arrangement, Term	cybn_OtherEquityInstrumentsInShareBasedPaymentArrangementTerm	18 months
Share-based Payment, Vesting, Period One [Member]
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	12,875,000
Number of Other Equity Instruments Issued in Share-Based Payment Arrangement	cybn_NumberOfOtherEquityInstrumentsIssuedInShareBasedPaymentArrangement	600,125
Private Placement [Member]
Share Price	cybn_SharePrice	$ 0.64
Milestone Transaction One [Member]
Increase (Decrease) Through Contingent Consideration, Equity	cybn_IncreaseDecreaseThroughContingentConsiderationEquity	$ 229,000
Milestone Transaction Two [Member]
Issue Of Equity, Contingent Consideration	cybn_IssueOfEquityContingentConsideration	$ 2,033,000
Euro Member Countries, Euro
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 386,000
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 535,000
United States of America, Dollars
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 662,000
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 827,000
United Kingdom, Pounds
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 456,000
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 749,000
Conversion Period Two [Member]
Convertible Stock, Shares Issued upon Conversion, Percentage	cybn_ConvertibleStockSharesIssuedUponConversionPercentage	66.667%
Conversion Period One [Member]
Convertible Stock, Shares Issued upon Conversion, Percentage	cybn_ConvertibleStockSharesIssuedUponConversionPercentage	33.333%
Conversion Of Stock, Tranche Three [Member]
Conversion Of Stock, Percentage Of Shares Exchangeable	cybn_ConversionOfStockPercentageOfSharesExchangeable	100.00%
Conversion Of Stock, Tranche Two [Member]
Conversion Of Stock, Percentage Of Shares Exchangeable	cybn_ConversionOfStockPercentageOfSharesExchangeable	66.667%
Conversion Of Stock, Tranche One [Member]
Conversion Of Stock, Percentage Of Shares Exchangeable	cybn_ConversionOfStockPercentageOfSharesExchangeable	33.333%
Accounts Payable And Accrued Liabilities [Member] \| Euro Member Countries, Euro
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 0
Accounts Payable And Accrued Liabilities [Member] \| United States of America, Dollars
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ (78,000)
Accounts Payable And Accrued Liabilities [Member] \| United Kingdom, Pounds
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ (29,000)
Cash [Member] \| Euro Member Countries, Euro
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 386,000
Cash [Member] \| United States of America, Dollars
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 740,000
Cash [Member] \| United Kingdom, Pounds
Financial Assets And Liabilities	cybn_FinancialAssetsAndLiabilities	$ 485,000
Phase 1, DMT Study [Member]
Asset Acquisition, Consulting Services, Maximum Expense	cybn_AssetAcquisitionConsultingServicesMaximumExpense	$ 480,000
Asset Acquisition, Consideration Transferred	cybn_AssetAcquisitionConsiderationTransferred	$ 1,000,000

AUDIT INFORMATION	12 Months Ended
AUDIT INFORMATION	Mar. 31, 2022
Audit Information [Abstract]
Auditor Name	Zeifmans LLP
Auditor Location	Toronto, Ontario
Auditor Firm ID	1149

CORPORATE INFORMATION (Details) $ in Thousands	Mar. 31, 2022 CAD ($)	Mar. 31, 2021 CAD ($)	Nov. 05, 2020
Corporate Information and Statement of IFRS Compliance [Abstract]
Reverse stock split conversion ratio			6.6672
Working capital	$ 50,447	$ 61,584

SIGNIFICANT ACCOUNTING POLICIES AND BASIS OF PREPARATION - Share-based compensation (Details)	12 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Exercisable period	10 years

SHARE CAPITAL - Summary of number and weighted average exercise prices of share options (Details)	12 Months Ended
	Mar. 31, 2022 $ / shares shares
Share Capital, Reserves, and Other Equity Interest [Abstract]
Number of options, cancelled (in shares) \| shares	(20,000)
Weighted average exercise price, cancelled (in dollars per share) \| $ / shares	$ 2.78

CONTRACTS AND COMMITMENTS (Details)	12 Months Ended
CONTRACTS AND COMMITMENTS (Details)	Mar. 31, 2022
COMMITMENTS [Line Items]
Expected payment period for contractual commitment	18 months

FINANCIAL INSTRUMENTS - Narrative (Details) $ in Thousands	12 Months Ended
FINANCIAL INSTRUMENTS - Narrative (Details) $ in Thousands	Mar. 31, 2022 CAD ($)
Disclosure of Financial Assets and Liabilities [Line Items]
Reasonably possible change in risk variable, percent	0.10
Reasonably possible change in risk variable, impact on net loss	$ 212

INCOME TAX - Income Tax Rate Reconciliation (Details) - CAD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Taxes [Abstract]
Share-based compensation	$ (4,778)	$ (3,099)
Share issuance costs	794	1,324
Change in unrecognized deferred tax assets	$ (11,282)	$ (6,626)

INCOME TAX - Non-capital Losses Expiration (Details) $ in Thousands	Mar. 31, 2022 CAD ($)
Canada
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	$ 50,045
United States
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	8,896
Ireland
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	9,469
2040 \| Canada
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	740
2041 \| Canada
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	19,193
2041 \| United States \| Pre-acquisition loss generated up to December 4, 2020
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	933
2041 \| United States \| Loss generated in the period from December 4, 2020 to March 31, 2021
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	1,241
2042 \| Canada
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	30,112
2042 \| United States \| Loss generated in the year ended March 31, 2022
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	6,722
2042 \| Ireland
Disclosure Of Non-Capital Losses Expiration [Line Items]
Non-capital losses	$ 9,469